Shanghai Kaibao Pharmaceutical CO.,LTD.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Shanghai Kaibao Pharmaceutical Co., Ltd. was established in 2000, mainly engaged in the research and development, production, and sales of modern Chinese medicine. The modern factory area was built with an investment of 600 million yuan and is located in the Shanghai Industrial Comprehensive Development Zone, covering an area of 120 acres. Listed on the Shenzhen Stock Exchange in 2010, it is the first listed company in Fengxian District (300039). Under its jurisdiction: Shanghai Kaibao Xinyi (Xinxiang) Pharmaceutical Co., Ltd., Shanghai Kaibao Equity Investment Management Co., Ltd., and Shanghai Kaibao Health Technology Co., Ltd., four wholly-owned subsidiaries. After 20 years of unremitting struggle, the company has won a series of honors and is a national modern Chinese medicine high-tech industrialization demonstration project base, one of the top 100 enterprises in the Chinese pharmaceutical industry. It is one of the first batch of Chinese medicine injection enterprises to pass the new GMP (2010 version) certification in China. In recent years, it has been ranked among the Fortune 100 in Fengxian District, Shanghai, and has made outstanding contributions to driving the local economy. Over the past decade since its listing, the company has achieved a cumulative output value of nearly 12 billion yuan, a cumulative tax payment of 2.4 billion yuan, a cumulative dividend of 1.17 billion yuan, and a conversion of 960 million shares, with outstanding results in returning to society; For 6 consecutive years, we have released social responsibility reports and actively fulfilled our social responsibilities. The company always adheres to the concept of "honesty and good medicine to save people" throughout every aspect of production and business activities. At present, the company and its subsidiaries have gradually built three product lines in the respiratory field represented by Tanreqing Injection, the cardiovascular and cerebrovascular field represented by Qishen Capsule, and the digestive field led by Tiopronin series products, further enhancing the company's product competitiveness and brand influence. The leading product of the company, Tanreqing Injection, is an exclusive patented product and a national protected product of traditional Chinese medicine. It belongs to the second category of new drugs of traditional Chinese medicine. It is the first batch of traditional Chinese medicine injections in China to use fingerprint detection technology for quality control throughout the entire process of medicinal materials, intermediates, and finished products. With its advanced process technology, excellent product quality, precise therapeutic effect, and extremely high safety, it has been listed as a clinical guideline or treatment plan by the National Health and Family Planning Commission and the Administration of Traditional Chinese Medicine in the prevention and control of major epidemics such as "human avian influenza", "H1N1 influenza", "H7N9 influenza", "hand, foot and mouth disease in children", "dengue fever", "Ebola", "Middle East respiratory syndrome", etc, As early as 2006, it was listed by the National Development and Reform Commission as "the reserved medicine of traditional Chinese patent medicines and simple preparations for influenza prevention and control" and became a national strategic reserved medicine, affirming the contribution of Tanreqing injection in the prevention and control of epidemic diseases. In 2020, Tanreqing injection was listed by the National Health Commission and the State Administration of Traditional Chinese Medicine as the recommended drug for severe and critical cases in the clinical treatment period of the Diagnosis and Treatment Plan for novel coronavirus Pneumonia (Trial Version 6/7/8), and was successively listed in the directory of TCM diagnosis and treatment plans for novel coronavirus Pneumonia in Beijing, Shanghai, Guangdong and other provinces and cities; Tanreqing capsule has been listed in the TCM diagnosis and treatment plan of novel coronavirus pneumonia by many provinces and cities, such as Shanghai and Anhui. Among them, Henan and Guizhou also listed it as a security drug for the prevention and control of COVID-19, making great contributions to the fight against COVID-19. The series of products Tanre Qing Capsules have been selected for the 2020 National Medical Insurance, providing convenient medication for mild patients and safeguarding the health of the people. The company has an independent and complete system for raw material procurement, research and development, production, and sales. Based on market demand and its own situation, market rules and operating mechanisms, it independently conducts production and business activities. Focusing closely on the annual business plan and goals, we have solidly promoted various work, and the overall business operation is relatively stable. In the past three years, the company's revenue has been around 1.5 billion yuan, and we have continued to promote the healthy and stable development of the enterprise through mergers and acquisitions, restructuring, and adhering to the combination of industry, academia, and research. The exclusive variety of Qishen Capsules, produced by subsidiary Xinyi Pharmaceutical, is a national new drug for treating coronary heart disease and angina pectoris of Qi deficiency and blood stasis type. Its main functions include supplementing qi, promoting blood circulation, resolving blood stasis, and relieving pain. It has the effect of improving myocardial function, reducing myocardial oxygen consumption, protecting myocardium, and has a good improvement effect on myocardial ischemia, hemodynamics, and hemorheology. Exclusive varieties of tiopronin sodium and tiopronin series products are used for the treatment of acute and chronic liver diseases, with a broad market and a good clinical application foundation. Especially tiopronin sodium for injection, it has exclusive patents, significant technological innovation and advantages, good stability, high safety, convenient use, and precise therapeutic effects, and has great potential in the field of liver disease treatment. The subsidiary Kaibao Health is mainly engaged in product development, market promotion, brand building and other major health industry projects in the field of health technology. The aim is to closely follow the rapid development of the national pharmaceutical and health industry, fully leverage the unique advantages of traditional Chinese medicine, take the research achievements of traditional Chinese medicine as the cornerstone, adhere to the concept of treating diseases before they occur, focus on prevention and assistance, and combine their own scientific research advantages to develop a series of products such as Xiaohao and Xihao, injecting new vitality into the company's strategic development and assisting the development of the health industry.The eternal pursuit of Shanghai Kaibao is to make medicine with integrity and save people with good medicine. Facing the future, Shanghai Kaibao will continue to move towards its strategic goals, fully tap into the enormous development potential of traditional Chinese medicine, rely on technological innovation, create high-quality Chinese medicine, innovate ethnic medicine, and inherit Chinese civilization. |
| Headquarter | Shanghai |
| Establish Date | 4/12/2000 |
| Listed Code | 300039.SZ |
| Listed Date | 1/8/2010 |
| Chairman | Mu Jingwei. |
| CEO | Wang Guoming. |
| Website | www.xykb.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
